PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) LEVEL AND 4G/5G GENETIC POLYMORPHISM IN PATIENTS WITH COLORECTAL CANCER

Bіasiak J., Smolarz B., Kubryn I., Kulig A., Dziki A., Ulanсska J., Pander B.

Summary. Plasminogen activator inhibitor-1(PAI-1) content in colorectal cancer tissue extracts may be of strong prognostic value: high levels of PAI-1 in tumors predict poor prognosis. PAI-1 gene is highly polymorphic, and an insertion (5G)/deletion (4G) polymorphism in the PAI-1 gene promoter (the 4G/5G polymorphism), may have functional significance in PAI-1 expression. In the present work PAI-1 level and distribution of genotypes and frequency of alleles of the 4G/5G polymorphism in 25 subjects with colorectal cancer in samples of cancer tissue and distant mucosa samples as well as in blood were studied. PAI-1 level was measured by ELISA, and the 4G/5G polymorphism was determined by PCR using allele specific primers. PAI-1 level in cancer tissue was significantly (P < 0.05) higher than in distant mucosa. No differences between genotypes of the 4G/5G polymorphism in distant mucosa, cancer tissue, and blood of each patient were found. The distribution of the genotypes in the population under study did not differ significantly (P > 0.05) from those predicted by Hardy-Weinberg distribution. The results support a hypothesis, that higher PAI-1 level is associated with colorectal cancer. Meanwhile 4G/5G polymorphism is not directly involved in the development of colorectal cancer.